• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.BRCA1、BRCA2和错配修复基因中的有害种系突变对人群卵巢癌的影响。
Hum Mol Genet. 2014 Sep 1;23(17):4703-9. doi: 10.1093/hmg/ddu172. Epub 2014 Apr 12.
2
High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.在阿拉伯裔乳腺癌和卵巢癌患者中,BRCA1 和 BRCA2 种系突变的高发率。
Breast Cancer Res Treat. 2018 Apr;168(3):695-702. doi: 10.1007/s10549-017-4635-4. Epub 2018 Jan 2.
3
Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.BRCA1 和 BRCA2 双重杂合性上皮性卵巢癌女性的临床病理特征:系统评价和病例报告分析。
Gynecol Oncol. 2020 Feb;156(2):377-386. doi: 10.1016/j.ygyno.2019.11.019. Epub 2019 Nov 18.
4
Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia.塞尔维亚高级别浆液性卵巢癌中癌症易感基因的种系突变
J Hum Genet. 2019 Apr;64(4):281-290. doi: 10.1038/s10038-019-0562-z. Epub 2019 Jan 16.
5
Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.特拉华州家族性胰腺癌的全州回顾性研究以及胰腺癌家族中基因突变的频率。
Ann Surg Oncol. 2016 May;23(5):1729-35. doi: 10.1245/s10434-015-5026-x. Epub 2016 Jan 4.
6
BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.中国卵巢癌患者的 BRCA1 和 BRCA2 突变:BRCA1 中的种族相关突变与卵巢癌风险增加相关。
Int J Cancer. 2017 May 1;140(9):2051-2059. doi: 10.1002/ijc.30633. Epub 2017 Feb 23.
7
BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.398 例卵巢癌患者的 BRCA1 和 BRCA2 突变与临床解读:与相似人群中乳腺癌变异体的比较。
Hum Genomics. 2018 Aug 13;12(1):39. doi: 10.1186/s40246-018-0171-5.
8
BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.BRCA1 和 BRCA2 未分类变异体及错义多态性在阿尔及利亚乳腺癌/卵巢癌家族中的研究。
Dis Markers. 2012;32(6):343-53. doi: 10.3233/DMA-2012-0893.
9
Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.台湾卵巢癌患者中BRCA1/2种系和体细胞突变的患病率及临床意义
Oncotarget. 2016 Dec 20;7(51):85529-85541. doi: 10.18632/oncotarget.13456.
10
Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.中国家族性乳腺癌/卵巢癌女性中BRCA1和BRCA2基因的新型种系突变及未分类变异
BMC Cancer. 2016 Feb 6;16:64. doi: 10.1186/s12885-016-2107-6.

引用本文的文献

1
Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer.外显子组测序将HELB鉴定为非黏液性、非高级别浆液性上皮性卵巢癌的一个新的易感基因。
Eur J Hum Genet. 2025 Mar;33(3):297-303. doi: 10.1038/s41431-025-01786-0. Epub 2025 Feb 12.
2
Prevalence of BRCA1 and BRCA2 mutations in ovarian cancer patients from Yunnan Province in southwest China.中国西南部云南省卵巢癌患者中BRCA1和BRCA2基因突变的患病率。
Eur J Cancer Prev. 2025 May 1;34(3):231-240. doi: 10.1097/CEJ.0000000000000931. Epub 2024 Oct 25.
3
Identification of ubiquitin markers for survival and prognosis of ovarian cancer.卵巢癌生存及预后相关泛素标志物的鉴定
Heliyon. 2024 Sep 7;10(18):e37288. doi: 10.1016/j.heliyon.2024.e37288. eCollection 2024 Sep 30.
4
Basic knowledge for counseling patients undergoing risk-reducing salpingo-oophorectomy.为接受降低风险的输卵管卵巢切除术的患者提供咨询的基础知识。
Obstet Gynecol Sci. 2024 Jul;67(4):343-355. doi: 10.5468/ogs.24054. Epub 2024 May 31.
5
The Molecular Detection of Germline Mutations in the and Genes Associated with Breast and Ovarian Cancer in a Romanian Cohort of 616 Patients.罗马尼亚616例患者队列中与乳腺癌和卵巢癌相关的BRCA1和BRCA2基因种系突变的分子检测
Curr Issues Mol Biol. 2024 May 12;46(5):4630-4645. doi: 10.3390/cimb46050281.
6
Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions.综合多组学分析鉴定卵巢癌风险区域的遗传和功能机制。
Am J Hum Genet. 2024 Jun 6;111(6):1061-1083. doi: 10.1016/j.ajhg.2024.04.011. Epub 2024 May 8.
7
Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System.巴西公共医疗体系中治疗的卵巢癌女性的 BRCA1 和 BRCA2 种系突变。
BMC Cancer. 2024 Apr 19;24(1):499. doi: 10.1186/s12885-024-12246-1.
8
Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2 ovarian cancer cells.靶向抑制 ATR/CHK1 通路可克服奥拉帕利耐药性,并调节 BRCA2 卵巢癌细胞中 DNA 损伤反应蛋白的表达。
Sci Rep. 2023 Dec 19;13(1):22659. doi: 10.1038/s41598-023-50151-y.
9
Landscape of germline variants in breast and ovarian cancer in Peru.秘鲁乳腺癌和卵巢癌种系变异情况
Front Oncol. 2023 Aug 17;13:1227864. doi: 10.3389/fonc.2023.1227864. eCollection 2023.
10
Diagnostic Scrutiny and Patterns of Elevated Cancer Risk: Uncovering Overdiagnosis Through Standardized Incidence Ratios.诊断审查与癌症风险升高模式:通过标准化发病率比值揭示过度诊断
Cureus. 2023 Jul 25;15(7):e42439. doi: 10.7759/cureus.42439. eCollection 2023 Jul.

本文引用的文献

1
The admixture maximum likelihood test to test for association between rare variants and disease phenotypes.混合最大似然检验用于检验罕见变异与疾病表型之间的关联。
BMC Bioinformatics. 2013 Jun 6;14:177. doi: 10.1186/1471-2105-14-177.
2
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.多个位于 TERT 基因座的独立变体与端粒长度和乳腺癌及卵巢癌的风险相关。
Nat Genet. 2013 Apr;45(4):371-84, 384e1-2. doi: 10.1038/ng.2566.
3
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.GWAS 荟萃分析和复制确定了三个新的卵巢癌易感性位点。
Nat Genet. 2013 Apr;45(4):362-70, 370e1-2. doi: 10.1038/ng.2564.
4
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer.表观遗传学分析导致鉴定出 HNF1B 为卵巢癌特定亚型的易感性基因。
Nat Commun. 2013;4:1628. doi: 10.1038/ncomms2629.
5
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.鉴定和分子特征分析 17q21.31 上新的卵巢癌易感性位点。
Nat Commun. 2013;4:1627. doi: 10.1038/ncomms2613.
6
Contribution of large genomic rearrangements in Italian Lynch syndrome patients: characterization of a novel alu-mediated deletion.意大利林奇综合征患者中大片段基因组重排的贡献:一种新型 Alu 介导缺失的特征。
Biomed Res Int. 2013;2013:219897. doi: 10.1155/2013/219897. Epub 2012 Dec 30.
7
Cancer statistics, 2013.癌症统计数据,2013 年。
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
8
Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction.对 30 个遗传性乳腺癌和卵巢癌家族的假定 BRCA1 剪接突变进行分析,确定了逃避计算机预测的外显子剪接突变。
PLoS One. 2012;7(12):e50800. doi: 10.1371/journal.pone.0050800. Epub 2012 Dec 11.
9
Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer.基于人群的卵巢癌女性错配修复基因突变频率研究。
Br J Cancer. 2012 Nov 6;107(10):1783-90. doi: 10.1038/bjc.2012.452. Epub 2012 Oct 9.
10
BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.BRCA基因携带者、预防性输卵管卵巢切除术与绝经:临床管理考量与建议
Womens Health (Lond). 2012 Sep;8(5):543-55. doi: 10.2217/whe.12.41.

BRCA1、BRCA2和错配修复基因中的有害种系突变对人群卵巢癌的影响。

The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.

作者信息

Song Honglin, Cicek Mine S, Dicks Ed, Harrington Patricia, Ramus Susan J, Cunningham Julie M, Fridley Brooke L, Tyrer Jonathan P, Alsop Jennifer, Jimenez-Linan Mercedes, Gayther Simon A, Goode Ellen L, Pharoah Paul D P

机构信息

CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK,

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

出版信息

Hum Mol Genet. 2014 Sep 1;23(17):4703-9. doi: 10.1093/hmg/ddu172. Epub 2014 Apr 12.

DOI:10.1093/hmg/ddu172
PMID:24728189
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4119409/
Abstract

The aim of this study was to estimate the contribution of deleterious mutations in BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2 to invasive epithelial ovarian cancer (EOC) in the population. The coding sequence and splice site boundaries of all six genes were amplified in germline DNA from 2240 invasive EOC cases and 1535 controls. Barcoded fragment libraries were sequenced using the Illumina GAII or HiSeq and sequence data for each subject de-multiplexed prior to interpretation. GATK and Annovar were used for variant detection and annotation. After quality control 2222 cases (99.2%) and 1528 controls (99.5%) were included in the final analysis. We identified 193 EOC cases (8.7%) carrying a deleterious mutation in at least one gene compared with 10 controls (0.65%). Mutations were most frequent in BRCA1 and BRCA2, with 84 EOC cases (3.8%) carrying a BRCA1 mutation and 94 EOC cases (4.2%) carrying a BRCA2 mutation. The combined BRCA1 and BRCA2 mutation prevalence was 11% in high-grade serous disease. Seventeen EOC cases carried a mutation in a mismatch repair gene, including 10 MSH6 mutation carriers (0.45%) and 4 MSH2 mutation carriers (0.18%). At least 1 in 10 women with high-grade serous EOC has a BRCA1 or BRCA2 mutation. The development of next generation sequencing technologies enables rapid mutation screening for multiple susceptibility genes at once, suggesting that routine clinical testing of all incidence cases should be considered.

摘要

本研究的目的是评估BRCA1、BRCA2、MLH1、MSH2、MSH6和PMS2基因中的有害突变对人群中浸润性上皮性卵巢癌(EOC)的影响。在2240例浸润性EOC病例和1535例对照的生殖系DNA中扩增了所有六个基因的编码序列和剪接位点边界。使用Illumina GAII或HiSeq对带条形码的片段文库进行测序,并在解读之前对每个受试者的序列数据进行解复用。使用GATK和Annovar进行变异检测和注释。经过质量控制后,最终分析纳入了2222例病例(99.2%)和1528例对照(99.5%)。我们发现193例EOC病例(8.7%)至少在一个基因中携带有害突变,而对照中有10例(0.65%)。BRCA1和BRCA2中的突变最为常见,84例EOC病例(3.8%)携带BRCA1突变,94例EOC病例(4.2%)携带BRCA2突变。在高级别浆液性疾病中,BRCA1和BRCA2联合突变患病率为11%。17例EOC病例在错配修复基因中携带突变,其中包括10例MSH6突变携带者(0.45%)和4例MSH2突变携带者(0.18%)。每10名高级别浆液性EOC女性中至少有1人携带BRCA1或BRCA2突变。下一代测序技术的发展使得能够同时快速筛查多个易感基因的突变,这表明应考虑对所有发病病例进行常规临床检测。